ClinicalTrials.gg
CompletedNCT00192140Updated Dec 28, 2007

Trial to Assess the Shedding,Immunogenicity, and Safety of FluMist Administered to Healthy Individuals 5-49 Years of Age

A Phase 4 interventional study of FluMist in Influenza, sponsored by MedImmune LLC. Completed at 11 sites in United States. Open to participants aged 5 Years to 49 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2007-12-28.

Sponsored by MedImmune LLC (part of AstraZeneca) · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
345
Allocation
Non-randomized
Ages
5 Years to 49 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 37 studies testing FluMist in Influenza, Human — 4 open to participants now, 7 under way, none of them phase 3. FluMist · Influenza, Human.

Enrollment
7th of 37
345 · median 72
Started
2004
with 2 others
Phase 4
21 of 37
3 open now
Registered
5th of 37
by date
Lead sponsor
8 of 37
MedImmune LLC

Among the 37 studies testing FluMist in Influenza, Human, this one is the 7th largest by enrollment, is one of 3 that started in 2004, is one of 21 in phase 4, and was the 5th registered.

Influenza, Human

2,358 studies on the registry are indexed under Influenza, Human; 184 are open to participants now.

Browse Influenza, Human studies →

Open to participants now

4 of the 37 studies testing FluMist in Influenza, Human are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About FluMist

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 121 Influenza, Human studies recruiting now, 66 (55%) set no upper age limit and 45 (37%) stop at 75 or younger; 33 take children under 18; 67 take healthy volunteers.

This study: 5 Years to 49 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 37 studies testing FluMist in Influenza, Human, or all of them as a file.
02

Study summary

  • To describe the proportion of individuals 5-49 years of age who shed vaccine strain viruses.
  • To describe the duration of shedding of vaccine viruses in individuals 5-49 years of age.
  • To describe the genotypic and phenotypic stability of shed vaccine viruses.
  • To describe the immune responses of FluMist in individuals 5-49 years of age.
  • To describe the safety of FluMist in individuals 5-49 years of age in relation to shedding and the immune response
Read the detailed description

The purpose of this study is to evaluate the viral shedding, immunogenicity and safety of FluMist when administered to healthy individuals between 5-49 years of age.

03

Conditions studied

  • Influenza

Browse trials for

04

Who can participate

Ages eligible
5 Years to 49 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 5-49 years of age;
  • In good health;
  • Individual or parent/guardian available by telephone;
  • Ability of the participant or parent/guardian to understand and comply with the requirements of the protocol; and
  • Signed and HIPAA authorization by the participant or parent/guardian.

Exclusion criteria

Exclusion Criteria:

  • History of to any component of FluMist, including egg or egg products;
  • History of hypersensitivity to gentamicin;
  • Close contact who is within the same household;
  • Known or suspected immune deficiency diseases or immunosuppressed or have altered or compromised immune status as a consequence of treatment with immunosuppressive therapies;
  • History of chronic underlying medical conditions such as chronic disorders of the cardiovascular and pulmonary systems, chronic metabolic diseases (including diabetes), renal dysfunction, or hemoglobinopathies;
  • History of Guillain-Barré syndrome;
  • History of asthma or reactive airways disease;
  • Acute febrile (>100.0°F oral) and/or respiratory illness, within the 72 hours prior to enrollment;
  • For children and adolescents - use of aspirin or aspirin containing products in the month prior to enrollment or anticipated use during the study;
  • Pregnancy or, in biologically capable women (e.g., menses within the last year), not willing to agree to acceptable for three months after enrolling into the study (for those biologically capable, a urine pregnancy test must be performed on the day of vaccination with a negative result);
  • Administration of any intranasal medication within two weeks prior to enrollment or expected receipt during this study;
  • Administration of any within one month prior to enrollment or if receipt of another live virus vaccine is expected within one month of the vaccination in this study;
  • Administration of any inactivated vaccine within two weeks prior to enrollment or if receipt of another inactivated vaccine is expected within two weeks of the vaccination in this study;
  • Participation in another trial or administration of any investigational drug within one month prior to enrollment or during this study;
  • Employees of the research center, any individuals involved with the conduct of the study, or any family member of such individuals;
  • Laboratory confirmed influenza (positive culture or rapid antigen test) in the prior influenza season (2003/2004 or 2004/2005 season);
  • Receipt of any influenza vaccine in the prior influenza season; and
  • Any condition that in the opinion of the investigator would interfere with the interpretation or evaluation of the vaccine.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
345 participants

Study arms

  • Active comparator
    1

    FluMist

    Biological: FluMist

Interventions

  • BiologicalFluMist

    A single intranasal dose of FluMist will be administered to approx. 300 subjects.

06

What researchers measure

Primary outcomes

  1. To describe the proportion of individuals 5-49 years of age who shed vaccine strain viruses.

    Time frame: 28 days after vaccination

  2. To describe the duration of shedding of vaccine viruses in individuals 5-49 years of age.

    Time frame: 28 days after vaccination

Secondary outcomes

  1. To describe the immune responses of FluMist in indivduals 5-49 years of age.

    Time frame: 28 days after vaccination

  2. To describe the safety of FluMist in individuals 5-49 years of age in relation to shedding and the immune response.

    Time frame: 28 days after vaccination

07

Study locations

11 sites
  • SFBC International, Inc
    Miami, Florida 33181, United States
  • Children's Memorial Hospital
    Chicago, Illinois 60614, United States
  • Kentucky Pediatric / Adult Research, Inc
    Bardstown, Kentucky 40004, United States
  • University of Maryland, School of Medicine
    Baltimore, Maryland 21201, United States
  • Center for Vaccine Development
    Saint Louis, Missouri 63110, United States
  • Creighton University Medical Center
    Omaha, Nebraska 68131, United States
  • Pediatric Clinical Trials International
    Columbus, Ohio 43205, United States
  • Primary Physician's Research Inc.
    Pittsburgh, Pennsylvania 15241, United States
  • Vanderbilt University Medical Center North
    Nashville, Tennessee 37232, United States
  • University of Virginia, Elson Student Health Center
    Charlottesville, Virginia 22904, United States
  • Marshall University Medical Center
    Huntington, West Virginia 25701, United States
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jun 2004, a primary completion of Oct 2004 and a completion of Jan 2005. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 9, 2005
First posted
Sep 19, 2005
Start
Jun 2004
Primary completionActual
Oct 2004
CompletionActual
Jan 2005
Last update
Dec 28, 2007
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 28, 2007, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00192140
Lead sponsor
MedImmune LLC
First posted
Sep 19, 2005
Start date
Jun 2004
Primary completion
Oct 2004
Completion
Jan 2005
Last update
Dec 28, 2007

Study contacts

Robert Walker, MD
study director · Sponsor GmbH

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2007. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: FluMist

Start the discussion